Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Olanzapine
95
CHF
CHF 95.00
In stock
CDX-O0143-G0011 gCHF 95.00
CDX-O0143-G0055 gCHF 380.00
| Product Details | |
|---|---|
| Synonyms | 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine; LY-170053 |
| Product Type | Chemical |
| Properties | |
| Formula |
C17H20N4S |
| MW | 312.43 |
| CAS | 132539-06-1 |
| RTECS | XJ9007750 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Yellow powder. |
| Solubility | Soluble in DMSO (10mg/ml) or DMF. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | KVWDHTXUZHCGIO-UHFFFAOYSA-N |
| Smiles | CN(CC1)CCN1C2=NC(C=CC=C3)=C3NC4=C2C=C(C)S4 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Olanzapine is a 5-HT2 serotonin and D1/D2 dopamine receptor antagonist, that binds to dopamine D1, D2, and D4 receptors (Ki=31, 11, and 27 nM, respectively) as well as the serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT2C and 5-HT3 (Ki=4, 11, and 57 nM, respectively). It also binds to M1 muscarinic acetylcholine, α1-adrenergic and histamine H1 receptors (Ki=2, 19, and 7 nM, respectively). Olanzapine is an atypical antipsychotic that displays anticholinergic properties. Olanzapine shows antidepressant-like activity. Formulations containing olanzapine have been used in the treatment of schizophrenia and bipolar disorder and for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.
Product References
(1) N.A. Moore, et al.; J. Pharmacol. Exp. Ther. 262, 545 (1992) | (2) F.P. Bymaster, et al.; Neuropsychopharmacol. 14, 87 (1996) | (3) G.D. Tollefson & C.C. Taylor; CNS Drug Reviews 6, 303 (2000) | (4) E. Nowakowska, et al.; Pharmacol. Rep. 66, 404 (2014) | (5) D.M. Ashby, et al.; Behav. Pharmacol. 26, 133 (2015) | (6) C. Fonte, et al.; Crit. Rev. Oncol. Hematol. 95, 214 (2015)